ES2193839A1 - Nuevos derivados de 6-fenildihidropirrolpirimidindiona. - Google Patents

Nuevos derivados de 6-fenildihidropirrolpirimidindiona.

Info

Publication number
ES2193839A1
ES2193839A1 ES200101452A ES200101452A ES2193839A1 ES 2193839 A1 ES2193839 A1 ES 2193839A1 ES 200101452 A ES200101452 A ES 200101452A ES 200101452 A ES200101452 A ES 200101452A ES 2193839 A1 ES2193839 A1 ES 2193839A1
Authority
ES
Spain
Prior art keywords
derivatives
phenyldihydropyrrolopyrimidinedione
organic residues
phenylpyrrolopyrimidinedione
heterocyclyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES200101452A
Other languages
English (en)
Other versions
ES2193839B1 (es
Inventor
Juan Bernat Vidal
Trias Cristina Esteve
Matamoros Victor Segarra
Rubira Enrique Ravina
Gonzalez Franco Fernandez
Garcia Maria Isabel Loza
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Almirall SA
Original Assignee
Almirall Prodesfarma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to ES200101452A priority Critical patent/ES2193839B1/es
Application filed by Almirall Prodesfarma SA filed Critical Almirall Prodesfarma SA
Priority to JP2003507097A priority patent/JP2004534828A/ja
Priority to PCT/EP2002/006727 priority patent/WO2003000694A1/en
Priority to US10/481,728 priority patent/US20050070558A1/en
Priority to EP02780834A priority patent/EP1409489A1/en
Priority to UY27349A priority patent/UY27349A1/es
Priority to ARP020102352A priority patent/AR036107A1/es
Priority to PE2002000540A priority patent/PE20030131A1/es
Publication of ES2193839A1 publication Critical patent/ES2193839A1/es
Application granted granted Critical
Publication of ES2193839B1 publication Critical patent/ES2193839B1/es
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Reproductive Health (AREA)
  • Otolaryngology (AREA)
  • Vascular Medicine (AREA)

Abstract

Nuevos derivados de 6-fenildihidropirrolpirimidindiona y sales farmacéuticamente aceptables de los mismos,**fórmula** en donde R1 R2, R3, R4 y R5 son restos orgánicos, L1 es un grupo de enlace y R6 es -C(O) NR10R11, -S(O)2NR10R11, -ON=CR12R13, o un grupo heterociclilo, arilo o heteroarilo, donde R10, R11, R12 y R13 son restos orgánicos, que tienen potencial terapéutico como inhibidores de receptor de adenosina A2.
ES200101452A 2001-06-22 2001-06-22 Nuevos derivados de 6-fenildihidropirrolpirimidindiona. Expired - Fee Related ES2193839B1 (es)

Priority Applications (8)

Application Number Priority Date Filing Date Title
ES200101452A ES2193839B1 (es) 2001-06-22 2001-06-22 Nuevos derivados de 6-fenildihidropirrolpirimidindiona.
PCT/EP2002/006727 WO2003000694A1 (en) 2001-06-22 2002-06-18 6-phenyldihydropyrrolopyrimidinedione derivatives
US10/481,728 US20050070558A1 (en) 2001-06-22 2002-06-18 6-Phenyldihydropyrrolopyrimidinedione derivatives
EP02780834A EP1409489A1 (en) 2001-06-22 2002-06-18 6-phenyldihydropyrrolopyrimidinedione derivatives
JP2003507097A JP2004534828A (ja) 2001-06-22 2002-06-18 新規６−フェニルジヒドロピロロピリミジンジオン誘導体
UY27349A UY27349A1 (es) 2001-06-22 2002-06-21 Nuevos derivados de 6-fenildihidropirrolpirimidindiona
ARP020102352A AR036107A1 (es) 2001-06-22 2002-06-21 Derivados de 6-fenilpirrolpirimidindiona, antagonista de los receptores a2 de la adenosina, particularmente del subtipo a2, de aplicacion en la prevencion de la degranulacion de los mastocitos; composiciones farmaceuticas formuladas con dichos compuestos y uso de los mismos en la preparacion de medi
PE2002000540A PE20030131A1 (es) 2001-06-22 2002-06-21 Derivados de 6-fenildihidropirrolpirimidindiona

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES200101452A ES2193839B1 (es) 2001-06-22 2001-06-22 Nuevos derivados de 6-fenildihidropirrolpirimidindiona.

Publications (2)

Publication Number Publication Date
ES2193839A1 true ES2193839A1 (es) 2003-11-01
ES2193839B1 ES2193839B1 (es) 2005-02-16

Family

ID=8498154

Family Applications (1)

Application Number Title Priority Date Filing Date
ES200101452A Expired - Fee Related ES2193839B1 (es) 2001-06-22 2001-06-22 Nuevos derivados de 6-fenildihidropirrolpirimidindiona.

Country Status (8)

Country Link
US (1) US20050070558A1 (es)
EP (1) EP1409489A1 (es)
JP (1) JP2004534828A (es)
AR (1) AR036107A1 (es)
ES (1) ES2193839B1 (es)
PE (1) PE20030131A1 (es)
UY (1) UY27349A1 (es)
WO (1) WO2003000694A1 (es)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2208063A1 (es) * 2002-04-01 2004-06-01 Almirall Prodesfarma, S.A. Nuevos derivados de la 4-(pirrolopirimidin-6-il)bencenosulfonamida.

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200403058A (en) * 2002-04-19 2004-03-01 Bristol Myers Squibb Co Heterocyclo inhibitors of potassium channel function
AR039385A1 (es) 2002-04-19 2005-02-16 Astrazeneca Ab Derivados de tioxantina como inhibidores de la mieloperoxidasa
ES2423800T3 (es) 2003-03-28 2013-09-24 Novartis Vaccines And Diagnostics, Inc. Uso de compuestos orgánicos para la inmunopotenciación
WO2004096225A2 (en) * 2003-04-28 2004-11-11 Ab Science Use of tyrosine kinase inhibitors for treating cerebral ischemia
PT1670458E (pt) 2003-10-08 2007-03-30 Schering Ag Derivados de tetra-hidronaftaleno, processo para a sua preparação e utilização como inibidor de inflamação
US7638515B2 (en) 2003-10-08 2009-12-29 Bayer Schering Pharma Aktiengesellschaft Tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents
US7662821B2 (en) 2003-10-08 2010-02-16 Bayer Schering Pharma Ag Tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents
SE0302756D0 (sv) * 2003-10-17 2003-10-17 Astrazeneca Ab Novel Compounds
MXPA06004789A (es) * 2003-10-31 2006-07-03 Cv Therapeutics Inc Antagonistas del receptor de adenosina a2b.
US20050165004A1 (en) * 2004-01-22 2005-07-28 Staffan Skogvall Bronchorelaxing compounds
US20080153859A1 (en) 2004-04-05 2008-06-26 Hartmut Rehwinkel Multiply-substituted tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents
SE0402591D0 (sv) * 2004-10-25 2004-10-25 Astrazeneca Ab Novel use
MY140748A (en) * 2004-12-06 2010-01-15 Astrazeneca Ab Novel pyrrolo [3,2-d] pyrimidin-4-one derivatives and their use in therapy
US20060167044A1 (en) * 2004-12-20 2006-07-27 Arnaiz Damian O Piperidine derivatives and their use as anti-inflammatory agents
DE102005017316A1 (de) * 2005-04-14 2006-10-19 Schering Ag Tetrahydronaphthalinderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Entzündungshemmer
EP1976841A4 (en) * 2005-12-19 2010-07-28 Neuromed Pharmaceuticals Ltd HETEROCYCLIC AMIDDERIVES AS CALCIUM CHANNEL BLOCKERS
EP1834948A1 (de) 2006-03-15 2007-09-19 Bayer Schering Pharma Aktiengesellschaft Tetrahydronaphthalinderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Entzündungshemmer
TW200804383A (en) * 2006-06-05 2008-01-16 Astrazeneca Ab New compounds
WO2007142577A1 (en) * 2006-06-05 2007-12-13 Astrazeneca Ab Pyrrolo[3,2-d]pyrimidin-4-one derivative as myeloperoxidase inhibitor
US7470697B2 (en) 2006-09-01 2008-12-30 Adenosine Therapeutics, Llc Pyrrolo[3,2-D] pyrimidines that are selective antagonists of A2B adenosine receptors
EP2268641B1 (en) 2008-03-26 2014-09-03 Advinus Therapeutics Pvt. Ltd. Heterocyclic compounds as adenosine receptor antagonist
US10517839B2 (en) 2008-06-09 2019-12-31 Cornell University Mast cell inhibition in diseases of the retina and vitreous
BRPI1009398A2 (pt) 2009-03-13 2016-03-08 Advinus Therapeutics Private Ltd compostos de pirimidina fundida substituída
SG184767A1 (en) 2009-03-23 2012-10-30 Glenmark Pharmaceuticals Sa Furopyrimidinedione derivatives as trpa1 modulators
JP5657638B2 (ja) * 2009-03-23 2015-01-21 グレンマーク ファーマシューティカルズ， エセ．アー． Ｔｒｐａ１調節因子としての縮合ピリミジンジオン誘導体
US8623880B2 (en) 2009-03-23 2014-01-07 Glenmark Pharmaceuticals S.A. Fused pyrimidine-dione derivatives as TRPA1 modulators
ES2424340T3 (es) 2009-03-23 2013-10-01 Glenmark Pharmaceuticals S.A. Derivados de isotiazolo-pirimidindiona como moduladores de TRPA1
JP5843778B2 (ja) 2009-11-09 2016-01-13 アドヴィナス・セラピューティックス・リミテッド 置換縮合ピリミジン化合物、その調製およびその使用
EP2571882A1 (en) * 2010-05-21 2013-03-27 Gilead Sciences, Inc. Heterocyclic flaviviridae virus inhibitors
CN103261200B (zh) 2010-09-13 2016-03-30 阿迪维纳斯疗法有限公司 作为a2b腺苷受体拮抗剂的前药的嘌呤化合物、它们的制备方法及医药用途
CN104350058A (zh) 2012-06-08 2015-02-11 格兰马克药品股份有限公司 2-氨基-4-芳基噻唑化合物的酰胺及其盐
CN103896953A (zh) * 2014-04-10 2014-07-02 广东众生药业股份有限公司 2,4-二羟基吡咯[2,3-d]嘧啶衍生物及其制备方法和用途
MX2017009608A (es) 2015-01-30 2017-11-20 Univ Sydney Compuestos anticancerigenos.
CN107007606B (zh) * 2016-02-04 2021-10-26 南京舒鹏生物科技有限公司 一种用于干燥综合症预防及治疗的药物及其组合
EP3720436A4 (en) 2017-12-06 2021-06-02 Lin Bioscience, Pty Ltd. TUBULIN INHIBITORS
BR112021016620A2 (pt) 2019-02-27 2021-11-03 Univ California Azepino-indóis e outros heterociclos para o tratamento de distúrbios cerebrais
JP2022523774A (ja) 2019-02-27 2022-04-26 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 脳障害を治療するためのｎ－置換インドール及び他の複素環化合物
WO2022167778A1 (en) 2021-02-02 2022-08-11 Haiku Therapeutics Ltd Ebselen as adenosine receptor modulator

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001094350A1 (en) * 2000-06-07 2001-12-13 Almirall Prodesfarma S.A. 6-phenylpyrrolopyrimidinedione derivatives

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4696932A (en) * 1984-10-26 1987-09-29 The United States Of America As Represented By The Department Of Health And Human Services Biologically-active xanthine derivatives

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001094350A1 (en) * 2000-06-07 2001-12-13 Almirall Prodesfarma S.A. 6-phenylpyrrolopyrimidinedione derivatives

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
FEOKTISTOV et al.: Adenosine A2B receptors. Pharmacological Reviews, 1997, Vol. 49 (4), pßginas 381-402, pßgina 387. *
GRAHNER, B. et al.: Synthesis and structure-activity relationships of deazaxanthines: analogs of potent A1 and A2 adenosine receptor antagonists. J. Med. Chem., 1994, Vol. 37 (10), pßginas 1526-1534, pßginas 1527-1530, tablas 1,2. *
JACOBSON, K. et al.: Functionalized congeners of 1,3-dialkylxanthines of analogues with high affinity for adenosine receptors. J. Med. Chem., 1985, Vol. 28 (9), pßginas 1334-1340, pßginas 1335-1336, tabla I. *
KIM, Y.C. et al.: Acyl-hydrazide derivatives of a xanthine carboxylic congener (XCC) as selective antagonists at human A2B adenosine receptors. Drug Development Research, 1999, Vol. 47, pßginas 178-188, pßgina 183, tabla 1. *
KIM, Y.C. et al.: Anilide derivatives of an 8-phenylxanthine carboxylic congener are highly potent and selective antagonists at human A2B adenosine receptors. J. Med. Chem., 2000, Vol. 43 (6), pßginas 1165-1172, tabla 2. *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2208063A1 (es) * 2002-04-01 2004-06-01 Almirall Prodesfarma, S.A. Nuevos derivados de la 4-(pirrolopirimidin-6-il)bencenosulfonamida.

Also Published As

Publication number Publication date
WO2003000694A1 (en) 2003-01-03
ES2193839B1 (es) 2005-02-16
AR036107A1 (es) 2004-08-11
US20050070558A1 (en) 2005-03-31
UY27349A1 (es) 2003-04-30
EP1409489A1 (en) 2004-04-21
JP2004534828A (ja) 2004-11-18
PE20030131A1 (es) 2003-04-10

Similar Documents

Publication Publication Date Title
ES2193839A1 (es) Nuevos derivados de 6-fenildihidropirrolpirimidindiona.
NO20054224L (no) Nye 2-pyridinkarboksamidderivater
AU2003248978A1 (en) Fused heteroaryl derivatives for use as p38 kinase inhibitors in the treatment of i.a. rheumatoid arthristis
NO986055L (no) Nye heterocykliske forbindelser, deres fremstilling, farmas°ytiske preparater inneholdende forbindelsene og deres anvendelse ved behandling av diabetes og beslektede sykdommer
BRPI0413232A (pt) novos compostos tendo atividade inibitória contra os trasnportadores dependentes de sódio
ATE344033T1 (de) Vinylphenyl-derivate als glk-aktivatoren
NO20062713L (no) 2,6 bisheteroaryl-4-aminopyrimidiner som adenosin reseptor antagonister
AU1282495A (en) Anthranilic acid derivative
DK1104760T3 (da) Sulfamoylheteroarylpyrazolforbindelser som anti-inflammatoriske/analgetiske midler
NO20082445L (no) Neuropeptid-2 reseptor-agonister
NO20062269L (no) Pyridin-karboksylsyrederivater som glucokinasemodulatorer
NO20051047L (no) Fremgangsmate og mellomprodukter for fremstilling av tienopyrrolderivater
YU72804A (sh) N-aril-2-oksazolidinon-5-karboksamidi i njihovi derivati i njihova primena kao antibakterijskih sredstava
NO20051008L (no) Nye imidazolforbindelser som transformerende vekst faktor (TGF) inhibitorer
PA8538501A1 (es) Inhibidores de benzotiadiazina de metaloproteinasas de la matriz
NO20031024D0 (no) Bicykliske pyrrolyl amider som glukogen fosforylase inhibitorer
WO2003011880A1 (fr) Derive de glucopyranosyloxybenzylbenzene, composition medicinale contenant ce derive, usage medicinal de cette composition et produit intermediaire pour produire cette composition
NO20052182L (no) Nye forbindelser
DK0734383T3 (da) Cykliske amidderivater som neurokinin-A-antagonister
NO324229B1 (no) 2-hydroksymutilinkarbamat-derivater, anvendelse derav, farmasoytisk sammensetning samt fremgangsmate for fremstilling av en slik forbindelse
EA200600046A1 (ru) Производные 6-[2-(фосфонометокси)алкокси]пиримидинов (варианты), способ их получения (варианты), фармацевтическая композиция на их основе и способ лечения вирусной инфекции
NO20071754L (no) Biotinylerte heksadekasakkarider, fremstilling og anvendelse derav
ATE275572T1 (de) Malto-oligosaccharid-derivate und ihre anwendungen
HUP0301882A2 (hu) Szubsztituált akriloil-disztamicin-származékok alkalmazása magas glutationszinttel kapcsolatos tumorok kezelésére
HUP0302255A2 (hu) Szulfonamidszármazékok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk

Legal Events

Date Code Title Description
EC2A Search report published

Date of ref document: 20031101

Kind code of ref document: A1

FG2A Definitive protection

Ref document number: 2193839B1

Country of ref document: ES

FD2A Announcement of lapse in spain

Effective date: 20180807